Pfister B, Imhof P, Wirz H
Eur J Clin Pharmacol. 1978 Jun 19;13(4):263-5. doi: 10.1007/BF00716361.
Investigations in six healthy volunteers given single oral doses of sulphinpyrazone (Anturan) showed that the drug had a potent uricosuric effect, even if the concentration of uric acid in the plasma was normal. In the dose range tested of 50 to 800 mg the increase in uric acid excretion was dose-related. It reached a maximum within 2 h and was still detectable 6--8 h after the drug was taken. There was a corresponding dose-related reduction in the plasma concentration of uric acid, which reached its lowest level after 8--10 h. The administration of 300 mg twice daily for four days to a further five healthy volunteers reduced plasma uric acid from 5.06 to 1.8 mg%. The findings indicate that, even if plasma uric acid levels are unknown, it would be advisable to avoid the risk of formation of urinary calculi by administering sulphinpyrazone in gradually increasing doses, ensuring adequate fluid intake and alkalinizing the urine during the first few days of treatment.
对六名单次口服磺吡酮（安妥明）的健康志愿者进行的研究表明，即使血浆中尿酸浓度正常，该药物仍具有强大的促尿酸尿作用。在50至800毫克的测试剂量范围内，尿酸排泄量的增加与剂量相关。服药后2小时内达到最大值，服药后6 - 8小时仍可检测到。血浆尿酸浓度相应地呈剂量相关下降，在8 - 10小时后降至最低水平。对另外五名健康志愿者每日两次给予300毫克，持续四天，可使血浆尿酸从5.06降至1.8毫克%。研究结果表明，即使血浆尿酸水平未知，在治疗的最初几天，通过逐渐增加磺吡酮剂量、确保充足的液体摄入并碱化尿液来避免形成尿路结石的风险是明智的。
